| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | UTE |
| Uniprot No | Q13336 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-389aa |
| 氨基酸序列 | MEDSPTMVRVDSPTMVRGENQVSPCQGRRCFPKALGYVTGDMKELANQLKDKPVVLQFIDWILRGISQVVFVNNPVSGILILVGLLVQNPWWALTGWLGTVVSTLMALLLSQDRSLIASGLYGYNATLVGVLMAVFSDKGDYFWWLLLPVCAMSMTCPIFSSALNSMLSKWDLPVFTLPFNMALSMYLSATGHYNPFFPAKLVIPITTAPNISWSDLSALELLKSIPVGVGQIYGCDNPWTGGIFLGAILLSSPLMCLHAAIGSLLGIAAGLSLSAPFEDIYFGLWGFNSSLACIAMGGMFMALTWQTHLLALGCALFTAYLGVGMANFMAEVGLPACTWPFCLATLLFLIMTTKNSNIYKMPLSKVTYPEENRIFYLQAKKRMVESPL |
| 预测分子量 | 42,5 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是模拟生成的关于“UTE重组蛋白”的参考文献示例(仅供格式参考，建议通过学术数据库查询真实文献)：
---
1. **文献名称**：*Expression and Functional Analysis of Recombinant UTE Protein in E. coli*
**作者**：Smith A, et al.
**摘要**：研究利用大肠杆菌系统高效表达UTE重组蛋白，优化了诱导条件及纯化步骤，并通过体外实验验证其与靶分子的结合活性，为后续疾病机制研究提供工具。
2. **文献名称**：*Structural Characterization of UTE Protein and Its Role in Cellular Signaling*
**作者**：Lee B, et al.
**摘要**：通过冷冻电镜解析了UTE重组蛋白的三维结构，揭示了其独特的结构域分布，并证明其在调控细胞凋亡通路中的关键作用。
3. **文献名称**：*Recombinant UTE Protein as a Novel Biomarker for Autoimmune Diseases*
**作者**：Chen C, et al.
**摘要**：探讨UTE重组蛋白在类风湿性关节炎患者血清中的高表达现象，证实其作为潜在诊断标志物的临床价值。
4. **文献名称**：*High-Yield Production of UTE Fusion Protein for Therapeutic Antibody Development*
**作者**：Wang X, et al.
**摘要**：开发了一种哺乳动物细胞表达系统，规模化生产具有生物活性的UTE-Fc融合蛋白，为抗体药物研发提供新策略。
---
**注意**：以上内容为模拟示例，实际文献需通过PubMed、Google Scholar等平台检索关键词“recombinant UTE protein”或结合具体研究领域细化搜索。
**Background of UTE Recombinant Protein**
Recombinant proteins, engineered through genetic modification, are produced by inserting target DNA sequences into host organisms (e.g., *E. coli*, yeast, or mammalian cells*) to express specific proteins. UTE recombinant protein, while not a universally standardized term, may refer to a customized or proprietary protein designed for specialized applications, potentially in biomedical research, therapeutics, or diagnostics. The "UTE" designation could denote unique structural features, functional properties, or target-specific modifications tailored for experimental or clinical use.
Recombinant technology enables precise control over protein production, ensuring high purity, scalability, and reproducibility—critical for research consistency and therapeutic safety. UTE recombinant proteins may be optimized for enhanced stability, solubility, or binding affinity, addressing challenges like aggregation or degradation in native proteins. Such modifications often involve codon optimization, fusion tags (e.g., His-tag for purification), or site-directed mutagenesis to improve functionality.
In drug development, recombinant proteins like monoclonal antibodies, enzymes, or cytokines have revolutionized treatments for cancers, autoimmune diseases, and genetic disorders. If UTE represents a therapeutic candidate, it might target specific pathways, receptors, or biomarkers, potentially offering advantages over conventional therapies. For instance, engineered proteins with extended half-lives or reduced immunogenicity are prioritized in biopharmaceutical pipelines.
Additionally, UTE recombinant proteins could serve as tools in structural biology (e.g., crystallography), diagnostic assays, or vaccine development. Their production in cost-effective microbial systems accelerates large-scale manufacturing, though complex proteins may require eukaryotic hosts for proper post-translational modifications.
Overall, UTE recombinant protein exemplifies the versatility of genetic engineering in creating tailored biomolecules to meet evolving scientific and medical demands, bridging gaps between laboratory discovery and real-world application.
在生物科技领域，蛋白研发与生产是前沿探索的关键支撑。艾普蒂作为行业内的创新者，凭借自身卓越的研发实力，每年能成功研发 1000 多种全新蛋白，在重组蛋白领域不断突破。 在重组蛋白生产过程中，艾普蒂积累了丰富且成熟的经验。从结构复杂的跨膜蛋白，到具有特定催化功能的酶、参与信号传导的激酶，再到用于免疫研究的病毒抗原，艾普蒂都能实现高效且稳定的生产。 这一成就离不开艾普蒂强大的技术平台。我们构建了多元化的重组蛋白表达系统，昆虫细胞、哺乳动物细胞以及原核蛋白表达系统协同运作。不同的表达系统各有优势，能够满足不同客户对重组蛋白的活性、产量、成本等多样化的需求，从而提供高品质、低成本的活性重组蛋白。 艾普蒂提供的不只是产品，更是从源头到终端的一站式解决方案。从最初的基因合成，精准地构建出符合要求的基因序列，到载体构建，为蛋白表达创造适宜的环境，再到蛋白质表达和纯化，每一个环节都严格把控。我们充分尊重客户的个性化需求，在表达 / 纯化标签的选择、表达宿主的确定等方面，为客户量身定制专属方案。 同时，艾普蒂还配备了多种纯化体系，能够应对不同特性蛋白的纯化需求。这种灵活性和专业性，极大地提高了蛋白表达和纯化的成功率，让客户的研究项目得以顺利推进，在生物科技的探索道路上助力每一位科研工作者迈向成功。
艾普蒂生物自主研发并建立综合性重组蛋白生产和抗体开发技术平台，包括： 哺乳动物细胞表达平台：利用哺乳动物细胞精准修饰蛋白，产出与天然蛋白相似的重组蛋白，用于药物研发、细胞治疗等。 杂交瘤开发平台：通过细胞融合筛选出稳定分泌单克隆抗体的杂交瘤细胞株，优化后的技术让抗体亲和力与特异性更高，应用于疾病诊断、免疫治疗等领域。 单 B 细胞筛选平台：FACS 用荧光标记和流式细胞仪快速分选特定 B 细胞；Beacon® 基于微流控技术，单细胞水平捕获、分析 B 细胞，挖掘抗体多样性，缩短开发周期。 凭借这些平台，艾普蒂生物为客户提供优质试剂和专业 CRO 技术服务，推动生物科技发展。
艾普蒂生物在重组蛋白和天然蛋白开发领域经验十分丰富，拥有超过 2 万种重组蛋白的开发案例。在四大重组蛋白表达平台的运用上，艾普蒂生物不仅经验老到，还积累了详实的成功案例。针对客户的工业化生产需求，我们能够定制并优化实验方案。通过小试探索、工艺放大以及条件优化等环节，对重组蛋白基因序列进行优化，全面探索多种条件，精准找出最契合客户需求的生产方法。 此外，公司还配备了自有下游验证平台，可对重组蛋白展开系统的质量检测与性能测试，涵盖蛋白互作检测、活性验证、内毒素验证等，全方位保障产品质量。 卡梅德生物同样重视蛋白工艺开发，确保生产出的蛋白质具备所需的纯度、稳定性与生物活性，这对于保障药物的安全性和有效性起着关键作用 ，与艾普蒂生物共同推动着行业的发展。
×
